FDA Approves Vyvgart (efgartigimod alfa) for Generalized Myasthenia Gravis
The FDA has approved Vyvgart (efgartigimod alfa) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Vyvgart is a neonatal Fc receptor blocker that reduces IgG levels, including pathogenic autoantibodies. The approval provides a new targeted therapy for this subset of gMG patients who often have limited treatment options. The recommended dosing is 10 mg/kg intravenously once weekly for 4 weeks, with subsequent cycles based on clinical evaluation. Clinicians should note that vaccination with live vaccines is not recommended during treatment due to transient reduction in IgG levels.
＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)
Vyvgart (efgartigimod alfa) is a neonatal Fc receptor (FcRn) blocker. It binds to FcRn, reducing the recycling of IgG, including pathogenic autoantibodies, leading to lower IgG levels.
Vyvgart is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
The recommended dosage is 10 mg/kg administered as an intravenous infusion over one hour once weekly for 4 weeks. For patients weighing 120 kg or more, the recommended dose is 1200 mg per infusion. Subsequent treatment cycles should be based on clinical evaluation. Vyvgart must be diluted with 0.9% Sodium Chloride Injection, USP to a total volume of 125 mL and administered via a 0.2 micron in-line filter. Evaluate the need for age-appropriate vaccines before each treatment cycle; live vaccines are not recommended during treatment.
Efficacy was established in a 26-week, multicenter, randomized, double-blind, placebo-controlled trial (Study 1; NCT03669588) in adults with gMG who are AChR antibody positive. Patients had MGFA class II to IV, MG-ADL total score ≥5, and were on stable MG therapy. Specific efficacy results are not detailed in the label.
Not reported in label.
Vyvgart offers a targeted FcRn blocker for anti-AChR antibody positive gMG patients. It is administered as a 4-week intravenous cycle and may be used in patients who require additional therapy despite standard treatments. The need for live vaccine avoidance and monitoring for hypersensitivity reactions should be considered.
View Original Abstract ↓
Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke
Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window
Related in Neurology
From Other Specialties
